Discovery of Adamantyl Ethanone Derivatives as Potent 11β-Hydroxysteroid Dehydrogenase Type 1 (11β-HSD1) Inhibitors
作者:Xiangdong Su、Fabienne Pradaux-Caggiano、Mark P. Thomas、Michelle W. Y. Szeto、Heather A. Halem、Michael D. Culler、Nigel Vicker、Barry V. L. Potter
DOI:10.1002/cmdc.201000081
日期:——
and cardiovascular diseases. A series of novel adamantyl ethanone compounds was identified as potent inhibitors of human 11β‐HSD1. The most active compounds identified (52, 62, 72, 92, 103 and 104) display potent inhibition of 11β‐HSD1 with IC50 values in the 50–70 nM range. Compound 72 also proved to be metabolically stable when incubated with human liver microsomes. Furthermore, compound 72 showed
11β-羟基类固醇脱氢酶(11β-HSD)是调节糖皮质激素激素受体代谢的关键酶。用选择性抑制剂调节11β-HSD1型活性可对各种状况产生有益的影响,包括胰岛素抵抗,血脂异常和肥胖。通过调节11β-HSD1抑制组织特异性糖皮质激素的作用,对于代谢性疾病和心血管疾病构成了一种有希望的治疗方法。一系列新的金刚烷基乙酮化合物被鉴定为人类11β-HSD1的有效抑制剂。最活跃的鉴定(化合物52,62,72,92,103和104)显示11β-HSD1的有效抑制与IC 50值在50–70 n M范围内。与人肝微粒体一起孵育时,化合物72也被证明在代谢上是稳定的。此外,化合物72对人细胞色素P450酶的抑制活性非常弱,因此是体内研究的候选药物。人类11β-HSD1的公开X射线晶体结构的比较导致了对有效化合物的对接研究,揭示了这些分子如何与酶和辅因子相互作用。